Literature DB >> 19897598

Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection.

Tze Howe Charn1, Edison Tak-Bun Liu, Edmund C Chang, Yew Kok Lee, John A Katzenellenbogen, Benita S Katzenellenbogen.   

Abstract

Estrogen receptors ERalpha and ERbeta, members of the nuclear receptor superfamily, exert profound effects on the gene expression and biological response programs of their target cells. Herein, we explore the dynamic interplay between these two receptors in their selection of chromatin binding sites when present separately or together in MCF-7 breast cancer cells. Treatment of cells (containing ERalpha only, ERbeta only, or ERalpha and ERbeta) with estradiol or ER subtype-selective ligands was followed by chromatin immunoprecipitation analysis with a custom-designed tiling array for ER binding sites across the genome to examine the effects of ligand-occupied and unoccupied ERalpha and ERbeta on chromatin binding. There was substantial overlap in binding sites for these estradiol-liganded nuclear receptors when present alone, but many fewer sites were shared when both ERs were present. Each ER restricted the binding site occupancy of the other, with ERalpha generally being dominant. Binding sites of both receptors were highly enriched in estrogen response element motifs, but when both ERs were present, ERalpha displaced ERbeta, shifting it into new sites less enriched in estrogen response elements. Binding regions of the two ERs also showed differences in their enrichments for other transcription factor binding motifs. Studies with ER subtype-specific ligands revealed that it was the liganded subtype that principally determined the spectrum of chromatin binding. These findings highlight the dynamic interplay between the two ERs in their selection of chromatin binding sites, with competition, restriction, and site shifting having important implications for the regulation of gene expression by these two nuclear receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19897598      PMCID: PMC2802902          DOI: 10.1210/me.2009-0252

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  52 in total

1.  Differential modulation of transcriptional activity of estrogen receptors by direct protein-protein interactions with the T cell factor family of transcription factors.

Authors:  M El-Tanani; D G Fernig; R Barraclough; C Green; P Rudland
Journal:  J Biol Chem       Date:  2001-08-24       Impact factor: 5.157

2.  Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists.

Authors:  S R Stauffer; C J Coletta; R Tedesco; G Nishiguchi; K Carlson; J Sun; B S Katzenellenbogen; J A Katzenellenbogen
Journal:  J Med Chem       Date:  2000-12-28       Impact factor: 7.446

3.  Human estrogen receptor beta-specific monoclonal antibodies: characterization and use in studies of estrogen receptor beta protein expression in reproductive tissues.

Authors:  I Choi; C Ko; O K Park-Sarge; R Nie; R A Hess; C Graves; B S Katzenellenbogen
Journal:  Mol Cell Endocrinol       Date:  2001-07-05       Impact factor: 4.102

Review 4.  Estrogen receptor beta in breast cancer.

Authors:  C Palmieri; G J Cheng; S Saji; M Zelada-Hedman; A Wärri; Z Weihua; S Van Noorden; T Wahlstrom; R C Coombes; M Warner; J-A Gustafsson
Journal:  Endocr Relat Cancer       Date:  2002-03       Impact factor: 5.678

5.  Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate.

Authors:  Anobel Tamrazi; Kathryn E Carlson; Jonathan R Daniels; Kyle M Hurth; John A Katzenellenbogen
Journal:  Mol Endocrinol       Date:  2002-12

6.  Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer.

Authors:  J Kurebayashi; T Otsuki; H Kunisue; K Tanaka; S Yamamoto; H Sonoo
Journal:  Clin Cancer Res       Date:  2000-02       Impact factor: 12.531

Review 7.  Mechanisms of estrogen action.

Authors:  S Nilsson; S Mäkelä; E Treuter; M Tujague; J Thomsen; G Andersson; E Enmark; K Pettersson; M Warner; J A Gustafsson
Journal:  Physiol Rev       Date:  2001-10       Impact factor: 37.312

8.  Differential modulation of DNA conformation by estrogen receptors alpha and beta.

Authors:  Jennifer R Schultz; Margaret A Loven; Vida M Senkus Melvin; Dean P Edwards; Ann M Nardulli
Journal:  J Biol Chem       Date:  2001-12-31       Impact factor: 5.157

9.  Kinetic analysis of estrogen receptor homo- and heterodimerization in vitro.

Authors:  Elisabeth Jisa; Alois Jungbauer
Journal:  J Steroid Biochem Mol Biol       Date:  2003-02       Impact factor: 4.292

10.  Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.

Authors:  P Roger; M E Sahla; S Mäkelä; J A Gustafsson; P Baldet; H Rochefort
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

View more
  69 in total

Review 1.  Estrogen signaling via estrogen receptor {beta}.

Authors:  Chunyan Zhao; Karin Dahlman-Wright; Jan-Åke Gustafsson
Journal:  J Biol Chem       Date:  2010-10-18       Impact factor: 5.157

Review 2.  Estrogen receptors and human disease: an update.

Authors:  Katherine A Burns; Kenneth S Korach
Journal:  Arch Toxicol       Date:  2012-05-31       Impact factor: 5.153

3.  Sharing the Roles: An Assessment of Japanese Medaka Estrogen Receptors in Vitellogenin Induction.

Authors:  Crystal S D Lee Pow; Erin E Yost; D Derek Aday; Seth W Kullman
Journal:  Environ Sci Technol       Date:  2016-07-26       Impact factor: 9.028

Review 4.  Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.

Authors:  Nalo Hamilton; Diana Marquez-Garban; Vei H Mah; Yahya Elshimali; David Elashoff; Edward B Garon; Jaydutt Vadgama; Richard Pietras
Journal:  Crit Rev Oncog       Date:  2015

Review 5.  Development of subtype-selective oestrogen receptor-based therapeutics.

Authors:  Stefan Nilsson; Konrad F Koehler; Jan-Åke Gustafsson
Journal:  Nat Rev Drug Discov       Date:  2011-09-16       Impact factor: 84.694

Review 6.  Impaired estrogen receptor action in the pathogenesis of the metabolic syndrome.

Authors:  Andrea L Hevener; Deborah J Clegg; Franck Mauvais-Jarvis
Journal:  Mol Cell Endocrinol       Date:  2015-05-29       Impact factor: 4.102

Review 7.  From in vivo gene targeting of oestrogen receptors to optimization of their modulation in menopause.

Authors:  Jean-François Arnal; Françoise Lenfant; Gilles Flouriot; Florence Tremollières; Henrik Laurell; Coralie Fontaine; Andrée Krust; Pierre Chambon; Pierre Gourdy
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

8.  Post-transcriptional regulation of human breast cancer cell proteome by unliganded estrogen receptor β via microRNAs.

Authors:  Giovanni Nassa; Roberta Tarallo; Giorgio Giurato; Maria Rosaria De Filippo; Maria Ravo; Francesca Rizzo; Claudia Stellato; Concetta Ambrosino; Marc Baumann; Niina Lietzèn; Tuula A Nyman; Alessandro Weisz
Journal:  Mol Cell Proteomics       Date:  2014-02-13       Impact factor: 5.911

Review 9.  Cancer therapy using natural ligands that target estrogen receptor beta.

Authors:  Gangadhara R Sareddy; Ratna K Vadlamudi
Journal:  Chin J Nat Med       Date:  2015-11

10.  ERβ- and prostaglandin E2-regulated pathways integrate cell proliferation via Ras-like and estrogen-regulated growth inhibitor in endometriosis.

Authors:  D Monsivais; M T Dyson; P Yin; J S Coon; A Navarro; G Feng; S S Malpani; M Ono; C M Ercan; J J Wei; M E Pavone; E Su; S E Bulun
Journal:  Mol Endocrinol       Date:  2014-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.